PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Rheumatoid arthritis: Biologics in second-line therapy show benefit

Positive effects for all drugs / long-term data and robust direct comparisons are lacking

2013-08-30
(Press-News.org) The German Institute for Quality and Efficiency in Health Care (IQWiG) examined 9 biotechnologically produced drugs for the treatment of adults with rheumatoid arthritis in whom prior pharmacological treatment had failed. According to the findings, for each drug the data provide proof, an indication, or at least a hint of a benefit in relation to at least one outcome criterion. This is the conclusion of the final report published by IQWiG on 26 August 2013.

In comparison to the preliminary report, additional data and studies confirm the positive effect of biologics. However, there is a lack of long-term data and robust direct comparisons of biologics with each other to be able to assess which of these drugs are better or less suited in second-line therapy.

Alleviation of pain and prevention of damage to joints

Rheumatoid arthritis is an autoimmune disease and the most common form of chronic inflammatory joint disease (0.5 to 1% of the EU population). Patients suffer from pain, fatigue and exhaustion, depressive moods, as well as functional limitations; these symptoms are accompanied by a loss of quality of life, independence and participation in social and occupational activities. The primary aim of treatment is thus to eradicate the symptoms of disease as far as possible and delay or prevent the destruction of joints (remission).

Nine biologics in second-line therapy

Disease-modifying antirheumatic drugs (DMARDs), among others, are used in the pharmacological treatment of rheumatoid arthritis, which, in contrast to anti-inflammatory drugs, intervene with the disease mechanism itself. Biotechnologically produced DMARDs (bDMARDs), called biologics, are harvested from living cell cultures.

The bDMARDs intervene at different points of the inflammation process via different mechanisms. Most of them inhibit the tumour-necrosis factor (TNF)-?, a factor that influences the inflammation process. According to treatment recommendations, the administration of a bDMARD is indicated as second-line therapy for patients in whom prior therapy failed to achieve the desired success or had no effect at all.

Nine such drugs were available in 2010 at the time IQWiG was commissioned to conduct the present benefit assessment: abatacept (trade name: Orencia), adalimumab (Humira), anakinra (Kineret), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi), infliximab (Remicade), rituximab (MabThera), and tocilizumab (RoActemra).

Treatment in placebo groups discontinued more frequently

A total of 35 studies were relevant for the present benefit assessment; however, some only reported results for subpopulations. In nearly all studies patients received the cytostatic drug methotrexate (MTX), which is used as basic therapy in inflammatory-rheumatoid diseases. One patient group additionally received a biologic; the control group mostly received placebo.

In 28 studies it was possible to adapt therapy if patients responded insufficiently to treatment. This occurred very frequently and was far more common in the placebo groups than in study participants treated with a biologic. Moreover, many participants discontinued the studies due to a lack of efficacy; this mainly applied to patients who had received placebo.

It is therefore possible that the results are biased for some outcome criteria. If possible, the impact of potential bias was tested by IQWIG using sensitivity analyses. According to the findings, despite potential bias, the effects found in the studies in favour of the biologics were often large enough, for example, to infer proof of a benefit instead of an indication of a benefit.

All biologics offer advantages

For 5 drugs (abatacept, adalimumab, certolizumab pegol, golimumab, and tocilizumab), proof of a benefit could be inferred for the outcome criteria "remission", "symptoms" (e.g. pain, swelling of joints, and morning stiffness), "physical functional status" and/or "quality of life". For the other 4 biologics (anakinra, etanercept, infliximab, and rituximab), there was no proof, but indications or at least hints of an advantage in relation to at least one of the outcome criteria.

However, for 3 drugs (adalimumab, certolizumab pegol, and tocilizumab) the data provided at least hints of harm from side effects (e.g. infections or study discontinuations due to adverse events). For the other 6 biologics, on the basis of the available studies the data provided no proof, indications or hints that these drugs caused such harm (or no such harm).

Hardly any direct comparisons available

Informative direct comparisons in which biologics were used according to their approval status are still lacking, as are long-term data on benefit and harm, even though some of the 9 biologics have been on the market for over 10 years. The biologics were solely compared with placebo in nearly all of the studies. However, direct comparisons are needed to draw robust conclusions on the comparison of biologics with each other. Only one direct comparison of 2 bDMARDs used in monotherapy (tocilizumab versus adalimumab) was relevant for the benefit assessment. As other relevant direct comparisons are lacking, it cannot yet be determined which of the 9 drugs are better or less suited in the second-line therapy of adults with rheumatoid arthritis.

Lack of long-term studies

Moreover, the placebo-controlled studies largely covered only a period of at most a year. However, side effects of biologics can also occur after longer periods of time. In addition, structural changes to joints, for which no data were recorded in any of the studies, can only be diagnosed after a longer period of time.

Because of the positive effects of biologics, placebo-controlled long-term studies on the research question investigated by IQWiG would not be ethically acceptable. This underlines the necessity of long-term direct comparisons, particularly for chronic diseases such as rheumatoid arthritis.

Additional data and study results

Changes to the final report in comparison to the preliminary report are predominantly caused by the changed data basis: On the one hand, IQWiG as usual updated the literature search; on the other, the drug manufacturers submitted supplementary information in the commenting procedure. For several of the drugs investigated, they submitted both new studies and new data on studies already included in the preliminary report.

At least 3 randomized controlled trials (RCTs) were available for 6 drugs: 6 each for abatacept, adalimumab and tocilizumab, 4 each for certolizumab and etanercept, and 3 for golimumab. Only 2 RCTs each were available for the benefit assessment of anakinra and rituximab and only 1 RCT was relevant for infliximab after a further study had to be excluded because the comparator drug (sulfasalazine) had not been administered in compliance with the approval status.

Stefan Lange, the Deputy Head of IQWiG, concludes: "In comparison to the preliminary report we were able to consider 7 further studies and several additional analyses. This again shows that transparency of scientific data and complete publication of all studies are worthwhile – for all parties involved. Unpublished data and insufficiently analysed studies can only cause harm."

###

Process of report production

IQWiG published the preliminary results in the form of the preliminary report in June 2012 and interested parties were invited to submit comments. At the end of the commenting procedure the preliminary report was revised and sent as a final report to the contracting agency, the Federal Joint Committee (G-BA), in July 2013. The submitted written comments were published in a separate document at the same time as the final report. The report was produced in collaboration with external experts.

The following German-language executive summary provides an overview of the background, procedures and further results of the report.

An English-language executive summary will be available soon. If you would like to be informed when the English document is available, please send an e-mail to info@iqwig.de.


ELSE PRESS RELEASES FROM THIS DATE:

Membranes contain beautiful patterns -- but their function is a mystery

2013-08-30
"We do not yet know what the possible biological function of this might be. There should be a reason for the patterns, we just have not discovered it yet", says associate professor Adam Cohen Simonsen, Department of Physics, Chemistry and Pharmacy, University of Southern Denmark. With his colleagues Jes Dreier, Jonathan Brewer, John Hjort Ipsen and Uffe Bernchou (now Odense University Hospital) from the research group MEMPHYS at Department of Physics, Chemistry and Pharmacy at the University of Southern Denmark, he has discovered that cell membranes can form spectacular ...

Little changes -- large effects

2013-08-30
Scientists at the University of York have discovered that very small chemical changes to dietary flavonoids cause very large effects when the plant natural products are tested for their impact on the human immune system. Plants are capable of making tens of thousands of different small molecules – an average leaf for example, produces around 20,000. Many of these are found in a typical diet and some are already known to have medicinal properties with effects on health, diseases and general well-being. Now plant biologists and immunologists at York have joined forces ...

UNC researchers find promising new angle for drugs to prevent stroke and heart attack

2013-08-30
CHAPEL HILL, N.C. – Platelets, which allow blood to clot, are at the heart of numerous cardiovascular problems, including heart attacks and stroke. New research has uncovered a key platelet protein that could offer a new angle for developing drugs to prevent thrombosis, or dangerous blood clots, in patients who are at high risk such as those with atherosclerosis or a history of heart problems. "I think we're at the start of an exciting journey of drug discovery for a new class of antithrombotic therapies," said lead study author Stephen Holly, PhD, assistant professor ...

Researchers identify new drug target for treating jet lag and shift work disorders

2013-08-30
University of Notre Dame researchers, as part of a collaborative effort, have identified a protein that potentially could be a target for drugs that that would help people recover faster from jet lag and better adjust their circadian rhythms during rotational shift work. The study appears in the Aug. 29th issue of the journal Cell. It can be found at: http://www.sciencedirect.com/science/article/pii/S0092867413009616 An internal circadian body clock helps virtually all creatures synchronize their bodily functions to the 24-hour cycle of light and dark in a day. However, ...

Rim Fire update -- Aug. 30, 2013

2013-08-30
Update for August 30, 2013 - The fire is over 201,00 acres as of 6 am this morning, Aug. 30, 2013 with containment at 32%. More than 40,000 acres of that fire have burned within Yosemite National Park. At least 111 structures have been destroyed by the fire, which has been burning since Aug. 17. According to Inciweb.org: "Burnout operations continued overnight in the southeastern area of the fire. Fire crews continued construction of fire line along 3N01 Road to stop fire spread to the north. Structure defense continues in all fires area. Today's plans are to continue ...

Researchers a step closer to finding cosmic ray origins

2013-08-30
The origin of cosmic rays in the universe has confounded scientists for decades. But a study by researchers using data from the IceCube Neutrino Observatory at the South Pole reveals new information that may help unravel the longstanding mystery of exactly how and where these "rays" (they are actually high-energy particles) are produced. Cosmic rays can damage electronics on Earth, as well as human DNA, putting astronauts in space especially at risk. The research, which draws on data collected by IceTop, the IceCube Observatory's surface array of detectors, is published ...

From cancer treatment to ion thruster

2013-08-30
Nanosatellites are smartphone-sized spacecraft that can perform simple, yet valuable, space missions. Dozens of these little vehicles are now tirelessly orbiting the earth performing valuable functions for NASA, the Department of Defense and even private companies. Nanosatellites borrow many of their components from terrestrial gadgets: miniaturized cameras, wireless radios and GPS receivers that have been perfected for hand-held devices are also perfect for spacecraft. However, according to Michigan Technological University's L. Brad King, there is at least one technology ...

NASA's TRMM sees heavy rain over Taiwan from Tropical Storm Kong-Rey

2013-08-30
NASA's Tropical Rainfall Measuring Mission or TRMM satellite flew directly above western Taiwan on August 28, 2013 at 2108 UTC when Tropical Storm Kong-Rey was dropping enormous amounts of rain. Kong-Rey is expected to affect Japan over the next several days while moving parallel to its western coastline. Flooding from torrential rainfall with totals of over 500 mm (~19.7 inches) have been reported in western Taiwan. A rainfall analysis from TRMM's Microwave Imager (TMI) and Precipitation Radar (PR) instruments revealed that precipitation was falling was at a rate of ...

BUSM researchers call for individualized criteria for diagnosing obesity

2013-08-30
(Boston) - With soaring obesity rates in the U.S., the American Medical Association has classified obesity as a disease. This major shift in healthcare policy brings much needed medical attention to obese patients. However, this definition of obesity focuses on a single criterion of Body Mass Index (BMI), which includes a large group of persons with high BMI who are metabolically healthy and not at high risk for type 2 diabetes, cardiovascular disease or obesity-associated cancers. In a review article published online in Endocrinology, Gerald V. Denis, PhD, professor ...

Satellite panorama of fizzling Juliette and 2 lows in Eastern Pacific

2013-08-30
Tropical Depression Juliette became post-tropical and two low pressure areas were struggling to develop in the Eastern Pacific Ocean on Aug. 30 when NOAA's GOES-West captured a beautiful panoramic image of all three systems. NOAA's GOES-West satellite sits in a fixed orbit that covers the western U.S. and the Pacific Ocean, providing imagery on a continual basis. NASA's GOES Project at the NASA Goddard Space Flight Center in Greenbelt, Md. created a panoramic image of the Pacific that showed the weakening post-tropical cyclone Juliette and two low pressure areas on Aug. ...

LAST 30 PRESS RELEASES:

Pink skies

Monkeys are world’s best yodellers - new research

Key differences between visual- and memory-led Alzheimer’s discovered

% weight loss targets in obesity management – is this the wrong objective?

An app can change how you see yourself at work

NYC speed cameras take six months to change driver behavior, effects vary by neighborhood, new study reveals

New research shows that propaganda is on the rise in China

Even the richest Americans face shorter lifespans than their European counterparts, study finds

Novel genes linked to rare childhood diarrhea

New computer model reveals how Bronze Age Scandinavians could have crossed the sea

Novel point-of-care technology delivers accurate HIV results in minutes

Researchers reveal key brain differences to explain why Ritalin helps improve focus in some more than others

Study finds nearly five-fold increase in hospitalizations for common cause of stroke

Study reveals how alcohol abuse damages cognition

Medicinal cannabis is linked to long-term benefits in health-related quality of life

Microplastics detected in cat placentas and fetuses during early pregnancy

Ancient amphibians as big as alligators died in mass mortality event in Triassic Wyoming

Scientists uncover the first clear evidence of air sacs in the fossilized bones of alvarezsaurian dinosaurs: the "hollow bones" which help modern day birds to fly

Alcohol makes male flies sexy

TB patients globally often incur "catastrophic costs" of up to $11,329 USD, despite many countries offering free treatment, with predominant drivers of cost being hospitalization and loss of income

Study links teen girls’ screen time to sleep disruptions and depression

Scientists unveil starfish-inspired wearable tech for heart monitoring

Footprints reveal prehistoric Scottish lagoons were stomping grounds for giant Jurassic dinosaurs

AI effectively predicts dementia risk in American Indian/Alaska Native elders

First guideline on newborn screening for cystic fibrosis calls for changes in practice to improve outcomes

Existing international law can help secure peace and security in outer space, study shows

Pinning down the process of West Nile virus transmission

UTA-backed research tackles health challenges across ages

In pancreatic cancer, a race against time

Targeting FGFR2 may prevent or delay some KRAS-mutated pancreatic cancers

[Press-News.org] Rheumatoid arthritis: Biologics in second-line therapy show benefit
Positive effects for all drugs / long-term data and robust direct comparisons are lacking